Alzheimer’s breakthrough – early success 30 years in the making
In November 2022, the pharmaceutical company Eisai released the full results from its phase 3 clinical trials of a new Alzheimer’s treatment drug called “lecanemab”. This is the first drug that has acted to successfully slow down the destruction of the brain in Alzheimer's by tackling the condition itself, rather than the symptoms it creates. This is achieved by reducing accumulations of an abnormal protein in the brain called amyloid.